May 2Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
Apr 25Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Nov 28, 2022Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Sep 21, 2022Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Apr 27, 2022Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Feb 4, 2022Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial
Feb 1, 2022ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints
Jun 21, 2021Anavex Life Sciences Announces ANAVEX®2-73 Biomarker Correlated with Efficacy Endpoint in Trial
Jun 14, 2021Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)
Apr 12, 2021Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board
Dec 21, 2020Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data
Dec 15, 2020Anavex Life Sciences Announces ANAVEX®2-73 Meets Primary and Secondary Endpoints in Clinical Trial
Sep 10, 2020Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial
Jun 16, 2020Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 U.S Phase 2 Trial
